Iovance Biotherapeutics, Inc. (IOVA) Stock

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. is led by CEO Frederick G. Vogt, publicly traded since 2010.

Iovance Biotherapeutics, Inc. (IOVA) stock trades at $14.09 with a market capitalization of $6.38B. The stock is valued at a negative price-to-earnings (P/E) ratio of -20.16, reflecting a net loss over the last twelve months, price-to-book of 8.63, price-to-sales of 19.39. Over the past 52 weeks the stock has ranged between $1.76 and $15.30, and currently trades 7.9% below its 52-week high.

On profitability, Iovance Biotherapeutics, Inc. generates a return on equity (ROE) of -40.51% (negative, reflecting a net loss), return on capital employed of -37.26%, an operating margin of -1.27%, a net profit margin of -89.09%.

Iovance Biotherapeutics, Inc. by the numbers, 2016–2025

Between 2016 and 2025 Iovance Biotherapeutics, Inc. reported revenue of $0 rising to $264.0M. Compounded, revenue has grown —% a year over five years, —% over three, 61.0% over the last twelve months. Net profit fell to $-391.0M.

The most recent net margin is -89.09%. On a trailing twelve-month basis to Jun '26, revenue is $324.0M and net profit $-289.0M.

Borrowings stand at $48.0M, cash from operations was $-302.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged -63.7% over five years, and was -55.9% in the most recent year.

The share price itself has compounded at -30.3% a year over five years, -21.4% over three, 76.1% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Iovance Biotherapeutics, Inc. (IOVA) — frequently asked questions